Expertise in
9
conditions

Javier M. Broto

Madrid, MD, ES 
Expertise in
9
conditions
Madrid, MD, ES 

Overview

Javier Broto practices practicing medicine in Madrid, Spain.

Mr. Broto is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Liposarcoma, Solitary Fibrous Tumor, and Gastrointestinal Stromal Tumor.

He is actively involved in clinical research, co-authoring 29 peer reviewed articles and participating in 10 clinical trials.

Gender

Male

Locations

Madrid, MD, Spain
Other Locations
Sevilla, AN, Spain
Badalona, CT 08916, Spain
Barcelona, CT, Spain
Mallorca, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2026
Intervention Type: Drug
Study Drugs: Letetresgene Autoleucel, Fludarabine, Cyclophosphamide
Study Phase: Phase 2
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor
Enrollment Status: Completed
Publish Date: August 07, 2026
Intervention Type: Drug
Study Drugs: Ramucirumab, Cyclophosphamide, Vinorelbine
Study Phase: Phase 1/Phase 2
Phase II Study on TSR-042 in Advanced Clear Cell Sarcoma
Phase II Study on TSR-042 in Advanced Clear Cell Sarcoma
Enrollment Status: Terminated
Publish Date: February 01, 2024
Intervention Type: Drug
Study Drug: TSR-042
Study Phase: Phase 2
Phase I/II Randomized Clinical Trial of Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma
Phase I/II Randomized Clinical Trial of Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma
Enrollment Status: Unknown
Publish Date: January 23, 2024
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 1
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Synovial Sarcoma
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Synovial Sarcoma
Enrollment Status: Terminated
Publish Date: September 13, 2023
Intervention Type: Drug
Study Drugs: Ramucirumab, Gemcitabine, Docetaxel
Study Phase: Phase 1/Phase 2
A Multicenter, Phase Ib/II Trial of Selinexor as a Single Agent and in Combination With Imatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GISTs)
A Multicenter, Phase Ib/II Trial of Selinexor as a Single Agent and in Combination With Imatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GISTs)
Enrollment Status: Unknown
Publish Date: March 27, 2023
Intervention Type: Drug
Study Drugs: Selinexor, Imatinib
Study Phase: Phase 1/Phase 2
A Phase II Open-Label Trial of Pazopanib Administered as a Single Agent in Patients With Unresectable or Metastatic Solitary Fibrous Tumor (SFT) and Extraskeletal Myxoid Chondrosarcoma (EMC)
A Phase II Open-Label Trial of Pazopanib Administered as a Single Agent in Patients With Unresectable or Metastatic Solitary Fibrous Tumor (SFT) and Extraskeletal Myxoid Chondrosarcoma (EMC)
Enrollment Status: Completed
Publish Date: March 27, 2023
Intervention Type: Drug
Study Drug: Pazopanib
Study Phase: Phase 2
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Completed
Publish Date: October 06, 2022
Intervention Type: Drug
Study Drugs: Avapritinib, Regorafenib
Study Phase: Phase 3
Phase II Trial of Nab-paclitaxel for the Treatment of Desmoid Tumors and Multiply Relapsed/Refractory Desmoplastic Small Round Cell Tumors and Ewing Sarcoma
Phase II Trial of Nab-paclitaxel for the Treatment of Desmoid Tumors and Multiply Relapsed/Refractory Desmoplastic Small Round Cell Tumors and Ewing Sarcoma
Enrollment Status: Completed
Publish Date: June 07, 2022
Intervention Type: Drug
Study Drug: Nab-Paclitaxel
Study Phase: Phase 2
Prospective Observational Study of the Expression of ABCB1 / P-glycoprotein as a Factor for the Biological Stratification of Non-metastatic Osteosarcoma of the Extremities
Prospective Observational Study of the Expression of ABCB1 / P-glycoprotein as a Factor for the Biological Stratification of Non-metastatic Osteosarcoma of the Extremities
Enrollment Status: Completed
Publish Date: August 04, 2021
View 9 Less Clinical Trials

29 Total Publications

Reply to: Mifamurtide in Nonmetastatic High-Grade Osteosarcoma.
Reply to: Mifamurtide in Nonmetastatic High-Grade Osteosarcoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 14, 2026

Frequently Asked Questions about Javier M. Broto

Is Javier M. Broto a top-rated expert for Adult Soft Tissue Sarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Javier M. Broto is classified as an Elite expert for Adult Soft Tissue Sarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Javier M. Broto participate in research or clinical trials?

Yes. Javier M. Broto has published 29 articles and abstracts on conditions like Adult Soft Tissue Sarcoma. You can view a list of Javier M. Broto's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Broto's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 7 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile